Proparacaine
- Generic Name
- Proparacaine
- Brand Names
- Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H26N2O3
- CAS Number
- 499-67-2
- Unique Ingredient Identifier
- B4OB0JHI1X
- Background
Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.
- Indication
Used as a local (ophthalmic) anesthetic.
- Associated Conditions
- Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)
- Associated Therapies
- Local Anaesthesia therapy
Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma
- First Posted Date
- 2021-05-11
- Last Posted Date
- 2021-10-05
- Lead Sponsor
- Celgene
- Registration Number
- NCT04882163
- Locations
- 🇬🇧
Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Avera Cancer Institute, Sioux Falls, South Dakota, United States
Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant
- Conditions
- Interventions
- First Posted Date
- 2021-05-06
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 20
- Registration Number
- NCT04876248
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients
- Conditions
- Interventions
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 899
- Registration Number
- NCT04824092
- Locations
- 🇨🇳
Morphsys Research Site, Taoyuan, Taiwan
🇬🇧MorphoSys Research Site, Wolverhampton, United Kingdom
🇷🇺Morphosys research site, UFA, Russian Federation
Dose Escalation and Expansion Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2021-03-26
- Last Posted Date
- 2021-11-12
- Lead Sponsor
- Keymed Biosciences Co.Ltd
- Target Recruit Count
- 87
- Registration Number
- NCT04818372
- Locations
- 🇨🇳
Beijing Chao-Yang Hospital, Capital Medical University (West Branch), Beijing, Beijing, China
🇨🇳Beijing Chao-Yang Hospital, Beijing, Beijing, China
🇨🇳Peking University Third Hospital, Beijing, Beijing, China
Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients
- Conditions
- Interventions
- First Posted Date
- 2021-03-17
- Last Posted Date
- 2021-12-06
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 50
- Registration Number
- NCT04802356
- Locations
- 🇪🇸
Hospital Gregorio Marañon, Madrid, Comunidad Autónoma De Madrid, Spain
🇪🇸Institut Catala d'Oncologia (ICO) Hospitalet, Hospitalet de Llobregat, Cataluña, Spain
🇪🇸Clinica Universidad Navarra (CUN), Pamplona, Navarra, Spain
Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL
- First Posted Date
- 2021-03-15
- Last Posted Date
- 2021-03-15
- Lead Sponsor
- Huiqiang Huang
- Target Recruit Count
- 30
- Registration Number
- NCT04796857
- Locations
- 🇨🇳
Department of Medical Oncology, Sun Yat-sen University Cancer Center,, Guangzhou, Guangdong, China
Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2021-03-11
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Brown University
- Target Recruit Count
- 52
- Registration Number
- NCT04792502
- Locations
- 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸Lifespan Cancer Insitute, Providence, Rhode Island, United States
Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma
- First Posted Date
- 2021-03-04
- Last Posted Date
- 2024-01-12
- Lead Sponsor
- US Oncology Research
- Target Recruit Count
- 100
- Registration Number
- NCT04782687
- Locations
- 🇺🇸
Maryland Oncology Hematology, P.A., Columbia, Maryland, United States
🇺🇸New York Oncology Hematology, P.C., Albany, New York, United States
🇺🇸Rocky Mountain Cancer Centers, Denver, Colorado, United States
DARA RVD For High Risk SMM
- Conditions
- Interventions
- First Posted Date
- 2021-03-01
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Omar Nadeem, MD
- Target Recruit Count
- 61
- Registration Number
- NCT04775550
- Locations
- 🇺🇸
Stamford Hospital, Stamford, Connecticut, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years).
- Conditions
- Interventions
- First Posted Date
- 2021-02-12
- Last Posted Date
- 2022-09-07
- Lead Sponsor
- Poitiers University Hospital
- Target Recruit Count
- 270
- Registration Number
- NCT04751877
- Locations
- 🇫🇷
CHU Poitiers, Poitiers, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.